Solstice Oncology
Updated: September 23, 2026
CEO - Caroline J. Loew
Country: USA | Funding: $225M (+)
Founded: 2026
Website: https://www.solsticeoncology.com
Solstice Oncology is a clinical stage immuno-oncology company. The company licensed the Fc-enhanced cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody, called porustobart, from China's Harbour BioMed to develop and commercialize the drug outside of China. The company has already taken porustobart into phase 2 development for microsatellite stable (MSS) stage II and III colon cancer.
Founded: 2026
Website: https://www.solsticeoncology.com
Solstice Oncology is a clinical stage immuno-oncology company. The company licensed the Fc-enhanced cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody, called porustobart, from China's Harbour BioMed to develop and commercialize the drug outside of China. The company has already taken porustobart into phase 2 development for microsatellite stable (MSS) stage II and III colon cancer.
